Antithrombotic therapy after percutaneous revascularization in patients on chronic oral anticoagulation treatment

REC: Interventional Cardiology (English Ed.)

Juan M. Ruiz-Nodar¹  José Luis Ferreiro² 

[1] Servicio de Cardiología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain;Área de Enfermedades del Corazón, Hospital Universitario de Bellvitge – IDIBELL, Universidad de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain;

关键词: Atrial fibrillation;    Percutaneous coronary intervention;    Stent;    Oral anticoagulation;   

DOI  :  10.24875/RECICE.M19000010

来源: DOAJ

【 摘 要 】

Abstract The antithrombotic treatment after percutaneous revascularization in patients with chronic indication for oral anticoagulation has always been a matter of great interest and complexity, basically because of the high ischemic and thromboembolic risk of this population and high hemorrhagic risk associated with combination therapy with antiplatelet and anticoagulant drugs. The actual invasive management of ischemic cardiomyopathy has made this population of patients grow and raised concerns on which the optimal drugs and therapeutic strategies really are. Yet despite the scarce scientific evidence available, different antithrombotic regimens have been studied over the last few years in an attempt to reduce hemorrhagic events without affecting the efficacy of the new combination therapies. The strategies studied have been based on shortening the duration of triple anticoagulation therapy, and even on the use of double anticoagulation therapy (anticoagulation plus one single antiplatelet drug) prioritizing clopidogrel. But it has been the arrival of direct-acting anticoagulants, with important clinical trials conducted on this population, that has provided us with relevant and fundamental information that will undoubtedly contribute to change the actual clinical practice.

【 授权许可】

Unknown